1,152 material Form 8-K filings that 918 companies we cover made with the SEC in October 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Zions Bancorporation reported third-quarter 2025 net earnings of $221 million, or $1.48 per diluted share, up from $204 million, or $1.37, a year earlier but down from $243 million, or $1.63, in the second quarter. Results also reflected a $50 million charge-off and a $10 million reserve tied to loans to two related companies where the bank detected apparent irregularities, and the bank has started legal action to recover the amounts owed.
Net interest income rose 8% to $672 million, and net interest margin was 3.28% versus 3.03% a year earlier.
Provision for credit losses was $49 million versus $13 million a year earlier, primarily due to two large related C&I loans.
Estimated CET1 capital ratio was 11.3%, compared with 10.7% a year earlier.
Tangible book value per common share rose 17% to $38.64.
STAAR Surgical released preliminary third-quarter 2025 net sales of $94.7 million, up 6.9% from $88.6 million a year earlier, ahead of its October 23, 2025 stockholder vote on the Alcon merger proposal. The increase relied heavily on a $25.9 million December 2024 China shipment paid in full in the quarter, while distributor orders in China fell and nine-month sales declined year over year. The figures are unaudited and subject to change before the 10-Q is filed.
Q3 2025 preliminary net sales of $94.7 million, up 6.9% from $88.6 million
$25.9 million from the December 2024 China shipment was recognized in Q3 2025 after payment in full
Net sales outside China grew 7.7%, while new orders from China distributors were lower
Nine-month 2025 sales were lower than the prior year, as China distributors reduced inventory by about $80 million to $85 million
Cleveland-Cliffs reported third-quarter 2025 results with revenue of $4.7 billion, down from $4.9 billion in the second quarter. The GAAP net loss narrowed to $234 million from $473 million, and adjusted EBITDA rose to $143 million from $94 million, which shows the steelmaker's losses shrinking even as sales declined. The company also lowered its full-year 2025 capital expenditure and SG&A expectations.
Revenue was $4.7 billion in Q3 2025, compared with $4.9 billion in Q2 2025.
Adjusted net loss was $223 million, or $0.45 per diluted share, versus $250 million, or $0.51 per share, in Q2 2025.
Adjusted EBITDA was $143 million, up from $94 million in Q2 2025.
Full-year 2025 capital expenditure expectation was cut to approximately $525 million from $600 million; SG&A expectation was cut to approximately $550 million from $575 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.